Algernon Pharmaceuticals Inc.
AGN
CNSX
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.09M | 962.10K | 1.21M | 1.22M | 1.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.16M | 1.10M | 1.59M | 1.70M | 2.14M |
| Operating Income | -1.16M | -1.10M | -1.59M | -1.70M | -2.14M |
| Income Before Tax | -1.26M | 214.80K | -272.30K | -377.30K | -1.97M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.26 | 0.21 | -0.27 | -0.38 | -1.97 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.26M | 214.80K | -272.30K | -377.30K | -1.97M |
| EBIT | -1.16M | -1.10M | -1.59M | -1.70M | -2.14M |
| EBITDA | -1.14M | -1.08M | -1.57M | -1.68M | -2.11M |
| EPS Basic | -0.05 | 0.02 | -0.01 | -0.03 | -0.08 |
| Normalized Basic EPS | -0.07 | -0.07 | -0.09 | -0.09 | -0.06 |
| EPS Diluted | -0.05 | 0.01 | -0.02 | -0.03 | -0.08 |
| Normalized Diluted EPS | -0.07 | -0.07 | -0.09 | -0.09 | -0.06 |
| Average Basic Shares Outstanding | 107.03M | 99.77M | 91.69M | 80.16M | 87.12M |
| Average Diluted Shares Outstanding | 107.03M | 99.77M | 91.69M | 80.16M | 87.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |